Search

Objective: To retrospectively analyze the changes of bone mineral density (BMD) and bone metabolism in the patients with secondary rheumatoid arthritis osteoporosis treated with zoledronic acid sodium for over 3 times, explore whether long-term use of zoledronic acid sodium could improve and maintain the BMD of the patients for a long time, and also to observe the effects of zoledronic acid sodium on bone metabolism markers of the patients. Methods: 124 patients with secondary rheumatoid arthritis osteoporosis treated with zoledronic acid sodium and hospitalized in Changhai Hospital, Naval Medical University from May 2010 to December 2015 were selected as the treatment group. The patients in the treatment group were treated with 6 g of calcium acetate, qd, Q.25 of cal ci triol, po, qd and 5 mg of zoledronic acid sodium, po, once every 12 months, by ivgtt. Another 124 patients with rheumatoid arthritis but without osteoporosis were selected as the control group and were also trea - ted with calcium acetate and calcitriol in the same way as the treatment group. The BMD values of Li-4 lumbar vertebra and bone metabolism markers of the patients in the two groups were detected and compared before treatment and after treatment for 1,2 and 3 years and a medical followup for over 3 years. Results: The BMD values of lumbar vertebra increased in both groups after treatment. However, the BMD values of the treatment group increased more significantly as compared with those of the co nt rol group (P<0.05). As compared with befo re treatment, the bo ne metabolism markers type I procollagen amino terminal pro peptide (PINP) and 25 hy d ro xy vit am in D (25-0H~D3) all increased significantly (P<0 .05), and p-collagen degradation products ((3-CTX) significantly decreased (PC0 .05). Conclusion: Zoledronic acid sodium combined with calcium and calcitriol could significantly improve the BMD value of lumbar vertebra in the patients with secondary rheumatoid arthritis osteoporosis. However, prolonged use of zoledronic acid sodium (for more than 3 times) is not directly correlated with application frequency. At the same time, this treatment has little effect on bone metabolism/which might effectively inhibit bone resorption and reduce bone turnover rate as well. [ABSTRACT FROM AUTHOR]

Objective To explore the safety and efficacy of vitamin E combined with raloxifene on the treatment of postmenopausal osteoporosis. Methods A total of 120 postmenopausal women were randomly divided into the treatment group and the control group. Postmenopausal women in the treatment group received vitamin E combined with raloxifene and those in the control group received raloxifene only. Bone mineral density (BMD) , serum bone metabolic index, cytokine level, the incidence of adverse reactions, and the incidence of fracture were measured in the two groups before and after 12 months of the treatment. Results BMD of the lumbar vertebrae (LI-4) and the left femoral neck increased significantly after 12 months of the intervention, while BMD of the treatment group was significantly higher than that of the control group (P<(). 05). After 12 months of the intervention, the levels of BGP, ALP, 1L-6, TNF-α, 1L-10, and TGF-(31 of both groups changed significantly. The levels of BGP, ALP, IL-6, TNL-a, IL-10, and TGE-fM changed more obviously in the treatment group compared with the control group (P <0.05). The incidence of fracture decreased significantly in the treatment group compared with the control group ( P<(). 05). The adverse drug reactions were not significantly different between the two groups (P>0. 05). Conclusion Vitamin E combined with raloxifene can effectively protect the hip and lumbar vertebra BMD, change the level of bone metabolism and inflammatory factors, reduce the incidence of fracture, and the safety is better. [ABSTRACT FROM AUTHOR]

Objective To compare the effects of enalapril and simvastatin on bone mineral density and bone metabolism in elderly patients with hypertension and osteoporosis. Methods From July 2013 to September 2015, 126 elderly patients with hypertension and osteoporosis were randomly divided into treatment group (n = 63) and control group (n = 63). Patients in the treatment group were treated with enalapril + simvastatin and those in the control group received enalapril only. Serum levels of osteocalcin (OC), type I collagen C-tcrminal peptide (s-CTX), bone-derived alkaline phosphatase (BAP), tartrate - resistant phosphatase - 5b (TRACP - 5b) and bone mineral density (lumbar spine anteroposterior, femoral neck, forearm and greater trochanter) were measured at baseline and 6 months after treatment. Results There were no significant differences between the two groups in bone mineral density and bone metabolic index at baseline (P> 0.05). After treatment, OC. BAP and BiMD of lumbar spine, femoral neck, forearm and greater trochanter significantly increased, and the levels of s-CTX and TRACP-5b significantly decreased (P < 0.05) in both groups. After treatment, OC, BAP, s-CTX, TRACP-5b and BMD of lumbar spine, femoral neck, forearm and greater trochanter of the treatment group were significantly better than those in the control group (P <0. 05). Conclusion Elderly hypertensive patients with osteoporosis received enalapril and simvastatin treatment for 6 months had significantly greater increase in bone mineral density than oral administration of enalapril alone. [ABSTRACT FROM AUTHOR]

Objective To investigate the influence of gestational diabetes mellitus (GDM) on bone mineral density (BMD) in primigravida and multipara. Methods Retrospective case analysis of 200 single birth multipara，who were divided into two groups: the GDM group had 100 women who were diagnosed GDM in primigravida，while the control group had 100 women with normal blood glucose in primigravida. All the pregnant women had BMD measured using ultrasound bone densitometer at early pregnancy and puerperium in primigravida and at early pregnancy in multipara. Results The two groups'early pregnancy and puerperium BMD in primigravida had no significant difference. The two groups' early pregnancy BMD in multipara had no significant difference. GDM group's puerperium BMD was lower than early pregnancy BMD，and the difference had statistical significance. The control group's puerperium BMD was not significantly different from their early pregnancy BMD. Conclusion GDM may cause a decline of BMD，and we should strengthen management to prevent the incidence of osteoporosis. [ABSTRACT FROM AUTHOR]

Objective To investigate the bone healthy condition of 112 over 40 years old women in early pregnancy． Methods Ultrasound bone densitometer was used to measure the bone mineral density of the distal radius in 112 early pregnant women above 40 years old， including 44 primipara and 68 multipara as group A，224 pregnant women of 35 － 39 years old as group B，and 224 pregnant women below 34 years old as group C． Serum calcium，serum phosphate，and serum total protein of the pregnant women were examined． Ｒesults There was 19. 6% osteopenia and 2. 7% osteoporosis in pregnant women above 40 years old． Bone mineral density，serum calcium，and serum phosphate were not statistically different comparing with those in women below 34 years old． Bone mineral density was not different between primipara and multipara． Body mass index had positive correlation with bone mineral density． Conclusion The bone mineral density of pregnant women above 40 years old is not statistically different with that in women below 40 years old． Measurement of bone mineral density is crucial for discovery and prevention of osteoporosis in early pregnancy． [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Osteoporosis is the property of Chinese Journal of Osteoporosis and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective To investigate the differences in bone mineral density and blood calcium between women with preeclampsia and normal pregnancy． Methods Retrospective case analysis was performed in 270 single birth gravida，who were divided into two groups: the preeclampsia group had 150 women who were diagnosed preeclampsia，while the control group had 120 women without preeclampsia and gestational hypertension． All pregnant women had ultrasound bone mineral density examination in early pregnancy using ultrasound bone densitometer． In addition，biochemical tests were performed in early and late pregnancy，which included calcium and iron concentration． Results The ultrasound bone mineral density of the preeclampsia group was significantly lower than that of the control group． The preeclampsia group's early pregnancy blood calcium was not statistically different from that of the control group，whereas the preeclampsia group's late pregnancy blood calcium was lower than that of the control group． The two groups' serum iron concentrations in early and late pregnancy were not significantly different． Conclusion The early pregnancy ultrasound bone mineral density and the blood calcium concentration have certain significance in predicting preeclampsia． [ABSTRACT FROM AUTHOR]